TickerFactsScreenerDevelopers

VYNE Therapeutics Inc. (VYNE) — Cash & Equivalents

Annual figures by fiscal year, from SEC filings.

2014: $273.0K2015: $43.81M2016: $4.03M2017: $10.21M2018: $27.87M2019: $43.76M2020: $57.56M2021: $42.25M2022: $30.91M2023: $30.62M2024: $19.93M2025: $24.03M$24.03M
2014Cash & Equivalents (USD)2025
Fiscal YearCash & EquivalentsChange YoY
2025$24.03M+20.6%
2024$19.93M-34.9%
2023$30.62M-0.9%
2022$30.91M-26.8%
2021$42.25M-26.6%
2020$57.56M+31.5%
2019$43.76M+57.0%
2018$27.87M+173.1%
2017$10.21M+153.4%
2016$4.03M-90.8%
2015$43.81M+15946.9%
2014$273.0K—